Integrating T cell metabolism in cancer immunotherapy

Dugnani, Erica; Pasquale, Valentina; Bordignon, Carlotta; Canu, Adriana; Piemonti, Lorenzo; Monti, Paolo

doi:10.1016/j.canlet.2017.09.039

Cited by 32 publications

(29 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 5-lncRNA signature might, therefore, be a molecular reference for understanding the interplay between ECM, and cancer and stromal cells which might be critical for cancer prevention [91]. The correlation with primary immunodeficiency, T cell activation, inflammatory response, and drug metabolism also implicates a role in the immune response to cancer [114]. The prognosis of cancer patients has been linked to the activation status of innate T cells which is the front line of host defense against cancer [115].…”

Section: Discussionmentioning

confidence: 99%

Identification of lncRNA Signature Associated With Pan-Cancer Prognosis

Bao

Wang

et al. 2021

IEEE J. Biomed. Health Inform.

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNAs) have emerged as potential prognostic markers in various human cancers as they participate in many malignant behaviors. However, the value of lncRNAs as prognostic markers among diverse human cancers is still under investigation, and a systematic signature based on these transcripts that related to pan-cancer prognosis has yet to be reported. In this study, we proposed a framework to incorporate statistical power, biological rationale, and machine learning models for pan-cancer prognosis analysis. The framework identified a 5-lncRNA signature (ENSG00000206567, PCAT29, ENSG00000257989, LOC388282, and LINC00339) from TCGA training studies (n=1,878). The identified lncRNAs are significantly associated (all P ≤1.48E-11) with overall survival (OS) of the TCGA cohort (n=4,231). The signature stratified the cohort into low-and high-risk groups with significantly distinct survival outcomes (median OS of 9.84 years versus 4.37 years, log-rank P=1.48E-38) and achieved a time-dependent ROC/AUC of 0.66 at 5 years. After routine clinical factors involved, the signature demonstrated better performance for long-term prognostic estimation (AUC of 0.72). Moreover, the signature was further evaluated on two independent external cohorts (TARGET, n=1,122; CPTAC, n=391; National Cancer Institute) which yielded similar prognostic values (AUC of 0.60 and 0.75; logrank P=8.6E-09 and P=2.7E-06). An indexing system was developed to map the 5-lncRNA signature to prognoses of pan-cancer patients. In silico functional analysis indicated that the lncRNAs are associated with common biological processes driving human cancers. The five lncRNAs, especially ENSG00000206567, ENSG00000257989 and LOC388282 that never reported before, may serve as viable molecular targets common among diverse cancers.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of lncRNA Signature Associated With Pan-Cancer Prognosis

Bao

Wang

et al. 2021

IEEE J. Biomed. Health Inform.

View full text Add to dashboard Cite

show abstract

“…[69] In addition to receptor clustering induced by the MHC-TCR interaction, co-stimulatory receptors on the T-cell surface could promoteT -cell activation and survival. [70] The Gliboa group developedam ultivalent agonistb ased on an aptamer against 4-1BB, ap rimary co-stimulatory receptor for T-cell activation. [71] They successfully used this DNA-based agonistt oc o-stimulate T-cells in vitro and significantly enhanced antitumor immunity in am ouse model.…”

Section: Regulation Of Cell Immunitymentioning

confidence: 99%

“…In addition to receptor clustering induced by the MHC–TCR interaction, co‐stimulatory receptors on the T‐cell surface could promote T‐cell activation and survival . The Gliboa group developed a multivalent agonist based on an aptamer against 4‐1BB, a primary co‐stimulatory receptor for T‐cell activation .…”

Section: Applicationsmentioning

confidence: 99%

Engineering Cell‐Surface Receptors with DNA Nanotechnology for Cell Manipulation

et al. 2019

View full text Add to dashboard Cite

Cell‐surface receptors play pivotal roles in the regulation of cell fate. Molecular engineering of cell‐surface receptors enables control of cell signaling and manipulation of cell behavior in a user‐defined way. Currently, the development of chemical‐biological approaches for non‐genetic engineering and regulation of membrane receptors is attracting significant interest. Recent research advances in functional nucleic acids and DNA nanotechnology have made it possible to use DNA as a new and promising molecular toolkit for controlling receptor‐mediated signaling and cell fates. In this minireview we summarize the advances in the use of DNA nanotechnology for the spatiotemporal regulation of cell receptors and highlight practical applications in manipulating cell functions including cell adhesion, cell–cell contact, cell migration, and cellular immunity. We also provide a perspective on the potential of and challenges facing DNA‐based receptor engineering in future applications of cell manipulation and cell‐based therapy.

show abstract

“…However, while for B-cell tumors in hematology the use of such manipulation was quite effective, the solid tumors were found to be less susceptible [8,9]. The reason is that the tumor itself can reduce the metabolic activity of T-cells [10,11].…”

Section: The Immune System Role In Oncogenesismentioning

confidence: 99%

Extracorporeal Immunotherapy in Oncology

2019

JCEI

View full text Add to dashboard Cite

Tumors development is closely related to the immune system state and in immunosuppression tumors occur many times more often. The quality of the immune defense depends on how the recognition system functions for malignized tumor cells and its timely destruction. However, the immunosuppression state may be a result of the tumor process itself. The tumor itself generates soluble molecules that inhibit the killer activity of lymphocytes and macrophages, which allows tumor cells to survive in the body. Therefore, it is justified to perform apheresis therapy aimed at removal of such inhibitors, and targeted restoration of cytotoxic activity of leukocytes, which should contribute to the tumor cells apoptosis. This method of extracorporeal immunopharmacotherapy is indicated not only in far-advanced cases, but also after any radical operations, when metastases are not detected and even chemotherapy is not carried out.

show abstract

Integrating T cell metabolism in cancer immunotherapy

Cited by 32 publications

References 77 publications

Identification of lncRNA Signature Associated With Pan-Cancer Prognosis

Identification of lncRNA Signature Associated With Pan-Cancer Prognosis

Engineering Cell‐Surface Receptors with DNA Nanotechnology for Cell Manipulation

Extracorporeal Immunotherapy in Oncology

Contact Info

Product

Resources

About